Search results for " Hyperandrogenism"

showing 10 items of 17 documents

Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?

2012

Abstract OBJECTIVE: To determine possible prediction of regular menses with aging in anovulatory women with polycystic ovary syndrome (PCOS). DESIGN: Cohort. SETTING: Academic practice. PATIENT(S): A total of 54 anovulatory women with PCOS and 28 age- and weight-matched control subjects. INTERVENTION(S): Blood and ovarian ultrasound at baseline and after 5 years. MAJOR OUTCOME MEASURE(S): Serum antimüllerian hormone (AMH), gonadotropins, androgens, insulin sensitivity, and ovarian ultrasound. RESULT(S): After 5 years, there was a significant decrease in AMH in women with PCOS and control subjects (10 of 54 anovulatory women became ovulatory after 5 years). There was a significant negative c…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyAgingSettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectSettore MED/13 - EndocrinologiaBody Mass IndexCohort StudiesPCOS AMH Fertility Ovarian function Ovulation Aging HyperandrogenismPredictive Value of TestsInternal medicinemedicineHumansProspective StudiesProspective cohort studyOvulationmedia_commonUltrasonographyAntimullerian Hormonebusiness.industryOvaryObstetrics and GynecologyMiddle AgedPolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEndocrinologyReproductive MedicinePredictive value of testsCohortAndrogensFemaleInsulin ResistancebusinessBody mass indexBiomarkersGonadotropinsCohort studyAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk fa…

2013

Abstract STUDY QUESTION: What alters cardiovascular and metabolic risk factors with aging in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Lipid parameters, mainly low-density lipoprotein (LDL) cholesterol, increase with aging, but not in women who attain ovulatory cycles. WHAT IS KNOWN ALREADY: Cardiovascular and metabolic parameters tend to increase with aging, but this has not been shown in a prospective longitudinal study in women with PCOS. Correlates of these changes have not been identified. STUDY DESIGN: A prospective cohort of 118 hyperandrogenic women with PCOS who were followed from the age of 20-25 years at 5 year intervals for 20 years. PARTICIPANTS/MATERIALS, SE…

AdultBlood GlucoseOvulationmedicine.medical_specialtyWaistSettore MED/09 - Medicina Internamedia_common.quotation_subjectmedicine.medical_treatmentBiologyBody Mass IndexSettore MED/13 - EndocrinologiaRisk FactorsInternal medicineTotal cholesterolPrevalencemedicineHumansInsulinLongitudinal StudiesGonadal Steroid HormonesOvulationmedia_commonMetabolic SyndromeCompeting interestsInsulinPolycystic ovary syndrome (PCOS)RehabilitationMetabolic riskAge Factorsnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseLipidsSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyReproductive MedicineCardiovascular DiseasesPCOS Cardiovascular risk aging hyperandrogenism ovarian function lipid alterationsFemalelipids (amino acids peptides and proteins)Waist CircumferenceMetabolic syndromePolycystic Ovary Syndrome
researchProduct

Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.

2005

CONTEXT: We undertook this study to estimate the prevalence of the various androgen excess disorders using the new criteria suggested for the diagnosis of polycystic ovary syndrome (PCOS). SETTING: The study was performed at two endocrine departments at the University of Palermo (Palermo, Italy). PATIENTS: The records of all patients referred between 1980 and 2004 for evaluation of clinical hyperandrogenism were reevaluated. All past diagnoses were reviewed using the actual diagnostic criteria. To be included in this study, the records of the patients had to present the following available data: clinical evaluation of hyperandrogenism, body weight and height, testosterone (T), free T, dehyd…

AdultHirsutismAdolescent17-alpha-HydroxyprogesteroneBody WeightOvaryAlopeciaBody HeightBody Mass IndexPelvisDiagnosis DifferentialPolycystic ovary syndrome HyperandrogenismNeoplasmsAcne VulgarisAndrogensHumansFemaleTestosteroneHyperandrogenismProgesteroneAnovulationPolycystic Ovary SyndromeRetrospective StudiesUltrasonography
researchProduct

Increasing adiposity in normal ovulatory women affects adipocytokine expression in subcutaneous and visceral abdominal fat

2008

Abstract Objective To determine which adipocytokines are differentially expressed as a function of body mass index (BMI), to compare expression of adipocytokines in abdominal subcutaneous and omental fat, and to correlate these findings with serum levels, BMI, and parameters of insulin resistance. Methods Serum and subcutaneous (sc) and omental (om) tissue were obtained from lean and obese ovulatory women undergoing gynecologic surgery. We determined adipocytokine expression in sc versus om abdominal fat and related this to increasing BMI. Results Serum leptin was higher and adiponectin lower in overweight subjects. Adipocytokines had higher expression in sc abdominal versus om adipose tiss…

AdultOvulationmedicine.medical_specialtySettore MED/09 - Medicina InternaAdipokineAdipose tissueIntra-Abdominal FatOverweightBody Mass IndexSettore MED/13 - EndocrinologiaInsulin resistanceAdipokinesADIPONECTIN OBESITY LEPTIN CARDIOVASCULAR RISK PCOS HYPERANDROGENISMInternal medicineHumansMedicineAdiposityAdiponectinbusiness.industryLeptinnutritional and metabolic diseasesObstetrics and GynecologyGeneral Medicinemedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaObesitySubcutaneous Fat AbdominalEndocrinologyCase-Control StudiesFemaleInsulin Resistancemedicine.symptombusinessBody mass indexhormones hormone substitutes and hormone antagonistsInternational Journal of Gynecology & Obstetrics
researchProduct

PCOS: metabolic impact and long-term management.

2012

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy in women, affecting up to 10% of those in reproductive age. Furthermore, PCOS presents a lifetime risk of type II diabetes, cardiovascular diseases and endometrial cancer. Women with PCOS have increased cardiovascular risk; however, the risk is not the same in all patients and it is necessary to assess an individual risk profile. There is a discrepancy between increased cardiovascular risk at young age and postmenopausal number of cardiovascular events, probablu depending on changes in androgen ovarian function after the forties. However, changes with age of metabolic profile in women with PCOS have not been studied yet an…

AdultSettore MED/09 - Medicina InternaAdolescentComorbiditySettore MED/11 - Malattie Dell'Apparato CardiovascolareMetforminSettore MED/13 - EndocrinologiaDiabetes Mellitus Type 2Cardiovascular DiseasesRisk FactorsObesity AbdominalPCOS Metabolic Syndrome Cardiovascular risk aging insulin resistance hyperandrogenismHypertensionHumansFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceChildAntihypertensive AgentsDyslipidemiasPolycystic Ovary SyndromeMinerva ginecologica
researchProduct

Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.

2008

Abstract BACKGROUND: Dyslipidemia is a common metabolic complication in polycystic ovary syndrome (PCOS). The aim of this study was to determine if differences exist in dyslipidemia in women with PCOS from different ethnic and geographical backgrounds. METHODS: This retrospective study evaluated the serum fasting lipid profiles of 106 women with PCOS from the United States and 108 women with PCOS from Italy evaluated at endocrinology clinics. RESULTS: American women had higher mean body mass index than Italian women (36.1+/-8.6 vs 28.1+/-5.8 kg/m2, p<0.01). Low HDL-cholesterol was the most prevalent lipid abnormality in both populations. U.S. women had higher mean levels of serum total chol…

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismEthnic groupPhysiologySettore MED/13 - EndocrinologiaBody Mass IndexCohort StudiesEndocrinologyRisk FactorsmedicinePrevalenceHumansObesityPCOS Hyperandrogenism Cardiovascular risk dyslipidemia LDL-cholesterolDyslipidemiasRetrospective StudiesGynecologybusiness.industryRetrospective cohort studyOverweightmedicine.diseaseObesityPolycystic ovarySettore MED/40 - Ginecologia E OstetriciaLipidsConfidence intervalUnited StatesItalyCardiovascular DiseasesFemalebusinessBody mass indexDyslipidemiaCohort studyPolycystic Ovary SyndromeJournal of endocrinological investigation
researchProduct

Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women

2008

Summary Objective  The aim of the present study was to determine if the favourable cardiopulmonary and metabolic benefits induced by exercise training (ET) programme are maintained after its cessation. Patients  Thirty-two young overweight polycystic ovary syndrome (PCOS) women matched for age and body mass index (BMI) with other 32 PCOS patients was enrolled. The first group [PCOS-T (trained)] underwent 24-week ET programme, whereas the second [PCOS-DT (detrained)] underwent 12-week ET programme followed by 12-week detraining period. Methods  At baseline, after 12- and 24-week follow-up, all PCOS women were studied for their hormonal (ovarian and adrenal androgens), metabolic (glucose and …

Blood GlucoseSettore MED/09 - Medicina Internaendocrine system diseasescardiopulmonary effectsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOverweightSettore MED/13 - EndocrinologiaBody Mass IndexEndocrinologyInsulinmedicine.diagnostic_testVO2 maxPCOS womenPolycystic ovaryfemale genital diseases and pregnancy complicationsRespiratory Function TestsCholesterolHeart Function Testspolicystic ovary syndromeFemalemedicine.symptomPhysical exercise training cardiovascular function pulmonary function PCOS hyperandrogenism insulin resistanceSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotoriePolycystic Ovary Syndromemedicine.medical_specialtyexercise training programmeLipoproteinsPhysical exerciseOxygen ConsumptionInternal medicinemedicineHumansExercise physiologyExerciseTriglyceridescardiopulmonary functionbusiness.industryInsulinMetabolic effects; cardiopulmonary effects; exercise training programme; PCOS womennutritional and metabolic diseasesOverweightCardiovascular riskSettore MED/11 - Malattie Dell'Apparato CardiovascolareMetabolic effectsEndocrinologystructured exercise training programmebusinessLipid profileBody mass index
researchProduct

The spectrum of androgen excess disorders.

2006

A better understanding of the different phenotypes and of their endocrine and metabolic characteristics permits investigators to distinguish three main androgen excess disorders: classic polycystic ovary syndrome (PCOS), mild ovulatory PCOS, and idiopathic hyperandrogenism. These androgenic phenotypes differ more for the severity of the endocrine and metabolic alteration than for the etiopathogenetic mechanisms. The appearance of a particular androgenic phenotype is determined by a sum of genetic and environmental factors, but mostly by body weight.

Malemedicine.medical_specialtymedicine.drug_classBiologyAndrogen ExcessDiagnosis DifferentialInsulin resistancePolycystic ovary syndrome hyperandrogenism androgen excess insulin resistance idiopathic hirsutismInternal medicinemedicineEndocrine systemHumanshirsutismHyperandrogenismObstetrics and Gynecologymedicine.diseaseAndrogenPhenotypePolycystic ovaryEndocrinologyReproductive MedicinePractice Guidelines as TopicAndrogensFemaleHyperandrogenismPolycystic Ovary SyndromeFertility and sterility
researchProduct

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

2009

Abstract OBJECTIVE: To review all available data and recommend a definition for polycystic ovary syndrome (PCOS) based on published peer-reviewed data, whether already in use or not, to guide clinical diagnosis and future research. DESIGN: Literature review and expert consensus. SETTING: Professional society. PATIENTS: None. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): A systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, to identify studies evaluating the epidemiology or phenotypic aspects of PCOS. RESULT(S): The Task Force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and c…

Ovulationmedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesMEDLINEPCOS Fertility Anovulation Menstrual irregularities Obesity Hyperandrogenism Ovarian function Ovarian ultrasoundsSettore MED/13 - EndocrinologiaDiagnosis DifferentialPredictive Value of TestsIntervention (counseling)Terminology as TopicEpidemiologymedicineHealth Status IndicatorsHumanshirsutismMenstruation DisturbancesOvarian Function TestsGynecologyEvidence-Based Medicinebusiness.industryHyperandrogenismOvaryObstetrics and GynecologyEvidence-based medicinemedicine.diseasePolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsPhenotypeReproductive MedicineFemalebusinessHyperandrogenismBiomarkersMedical literatureClinical psychologyPolycystic Ovary SyndromeFertility and sterility
researchProduct

Estroprogestins and cardiovascular risk in Polycystic Ovary Syndrome

2013

Because PCOS women present an increased cardiovascular risk, the safety of estroprogestin treatment is debated and contrasting data have been reported. However, cardiovascular risk is not the same in all PCOS women and individual cardiovascular risk should be assessed before staring any estroprogestin treatment. The available data show that products containing both second generation and third generation progestins (including drosperinone and cyproterone acetate) represent a safe treatment in PCOS patients with regular cardiovascular risk. In PCOS patients with increased cardiovascular risk, a careful choice of estroprogestin product is needed and cardiovascular risk should be monitored duri…

PCOS Estroprogestins Cardiovascular risk contraception hyperandrogenismSettore MED/40 - Ginecologia E OstetriciaSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/13 - Endocrinologia
researchProduct